Identity and synonyms
Identity follows the supplied name and synonyms; no additional identity description is supplied.
Synonyms: Nicotinamide adenine dinucleotide
Nonpeptide agent · Cofactor, nucleoside or nucleotide
Detailed molecular class: Non-peptide dinucleotide coenzyme
Supplied sequence or chemical reference
PubChem CID: 5892
Molecular formula: C21H27N7O14P2
IUPAC: [[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate
Source: PC-NAD
Database chemical reference; does not certify supplier vial, salt, isomer or formulation.
Mechanism
Redox coenzyme and substrate for NAD-consuming enzymes; cellular role does not establish infusion benefit.
Evidence and critical reading
Reported scientific and empirical uses
Mitochondrial research · Replacement and nutritional context
Nonpeptide cofactor commercially used in infusions and energy/longevity programs.
Human evidence
2019 metabolomic pilot and 2026 retrospective tolerability comparison do not prove rejuvenation, addiction treatment or cognitive benefit.
Preclinical evidence
NAD pathway experiments cannot establish equivalent effects of NAD, NR and NMN products.
Critical reading and limitations
A metabolic study and retrospective tolerability pilot do not demonstrate rejuvenation or validated addiction treatment.
Evidence applies to the exact molecule, formulation, route, population and endpoint studied. Supplier identity, purity and clinical equivalence are unverified.
Source-specific regimens
Descriptive source observations, not individual recommendations.
Regulatory product labeling
No numerical human dose is assigned: reviewed sources did not verify a regimen attributable to this material, route and indication. Other molecules’ doses, animal exposures, vial amounts and dietary requirements are not substituted.
Human-study exposure
No numerical human dose is assigned: reviewed sources did not verify a regimen attributable to this material, route and indication. Other molecules’ doses, animal exposures, vial amounts and dietary requirements are not substituted.
Empirical handbook
No numerical human dose is assigned: reviewed sources did not verify a regimen attributable to this material, route and indication. Other molecules’ doses, animal exposures, vial amounts and dietary requirements are not substituted.
Regulation and safety
Jurisdiction-specific regulatory context
No anti-aging medicinal authorization established in this review; supplement/product status is jurisdiction-specific.
Adverse effects and unknowns
2026 report describes GI symptoms, tachycardia and chest pressure during NAD infusions. Small observational design cannot establish population safety.
The comparative pilot reported chest pressure, GI symptoms and tachycardia; route/precursor differences matter.
Contraindications
See supported safety statements and exact product label; a complete contraindication set has not been established for this catalog material.
A complete list must match the exact authorized product. For experimental materials without verified human labeling, a complete contraindication set is not established here. No list does not mean safety.
Interactions
Only explicitly cited interactions may be asserted; unstudied combinations remain unknown, not interaction-free.
Separate documented interaction, pharmacologic plausibility and unknown interaction. Absence of a blend trial does not establish compatibility.
Studies and trials
Selected studies
No selected studies are attributed in this record.
Trials attributed in the package
No trials are attributed in this record.
Trial registration does not establish efficacy or validate commercial material.
Query candidates; attribution pending
NAD+ · 267 unfiltered query results, not authenticated trials
Query verification: October 16, 2026
Exact phrase intervention query; first three most recently updated records, not exhaustive. Aliases may be missed and heterogeneous products may appear. The total is the unfiltered registry query count, not authenticated trials. Source-integrity holds are excluded from ordinary listings.
View trial registry queryNCT07808333 · Nicotinamide for Retinal Protection in Primary Open-Angle Glaucoma (NADIR Trial)Registry status: Not yet recruitingLast update posted: October 13, 2026Query verification: October 16, 2026
NCT06726369 · A Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of MK-6204 (SKB535) for Injection in Participants With Advanced Solid TumorsRegistry status: RecruitingLast update posted: October 13, 2026Query verification: October 16, 2026
NCT07144527 · Nicotinamide Mononucleotide Supplementation for Exercise Tolerance Improvement in Healthy Older AdultsRegistry status: RecruitingLast update posted: October 7, 2026Query verification: October 16, 2026
Source issues and references
References include queries and bibliographic handbook attributions; not all are clinical studies. Human review remains pending.
- PC-NAD
October 16, 2026
- PMID31572171
Grant R, Berg J, Mestayer R, Braidy N, Bennett J, Broom S, Watson J.
October 16, 2026
- PMID41704678
Reyna K, Heinzen G, Patel N, Ritter M, Siojo A, Legere H, Pojednic R.
October 16, 2026
- pdf01
PEPNEXA 2.pdf
October 16, 2026
- pdf02
ELLA PEPTIDES.pdf
October 16, 2026
- pdf03
zlz list 26.8.5.pdf
October 16, 2026
- pdf05
PEPNEXA.pdf
October 16, 2026
- pdf07
US Peptide MangerCorp(1).pdf
October 16, 2026
- pdf09
PeptideFactory.pdf
October 16, 2026